ClinicalTrials.gov
public full text
Public Domain
Anti-LPS Antibody Treatment for Pediatric NAFLD
The main objective of this pilot study is to evaluate whether 12 weeks of IMM-124E in children with nonalcoholic fatty liver disease (NAFLD) in combination with standard of care treatment will decrease inflammation in the liver as measured by alanine transaminase (ALT). Specifically, investigators will measure percent change in ALT from Week 0 to Week 12 in treatment compared to placebo.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Moderately Carbohydrate-restricted Diet to Treat NAFLD in Adolescents#1153590
- Effect of a Low AGE Diet on Liver Function in Adults With Fatty Liver.#883936
- Global trends, epidemiological patterns, and disability burden of metabolic dysfunction-associated steatotic liver disease-related cirrhosis from 1990 to 2021: A comprehensive analysis of the Global Burden of Disease study.#196032
- MRI Based Biomarkers in Pediatric Autoimmune Liver Disease#1031035
- Beta-Hydroxybutyrate Feasibility Treating IBD#1137457
Record · ID 981886
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive